Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 13 min ago
Peer-reviewedLicence not statedMovement Disorders Clinical Practice

Efficacy and Safety of Omaveloxolone in Friedreich Ataxia: Real‐World Data from an Advanced Disease Cohort

  • Silvia Gallo1
  • Carlo Alberto Artusi2
  • Claudia Ledda1,3
  • Serena Budicin1,2
  • Gabriele Imbalzano1,2
  • Cecilia Buzzelli1
  • Elena Scaglia2
  • Francesca Donetto2
  • Elisa Montanaro4
  • Alberto Romagnolo1,2
  • Maurizio Zibetti1,2
  • Mario Giorgio Rizzone1,2
2 more authors
  • Marco Bozzali1,2
  • Leonardo Lopiano1,2
4 affiliations
  1. 1Department of Neuroscience “Rita Levi Montalcini” University of Turin Turin Italy
  2. 2Department of Neuroscience, Biomedicine and Movement University of Verona Verona Italy
  3. 3SC Neurologia 2U AOU Città della Salute e della Scienza di Torino Turin Italy
  4. 4Clinical Psychology Unit AOU Città Della Salute e Della Scienza di Torino, Corso Bramante 88 Turin Italy
Read full textPDFDOICite

Related

  1. 563 Updated safety and efficacy of AN4005, an oral small-molecule PD-L1 inhibitor, in advanced solid tumors: phase I dose-escalation and expansion
    Jing Chen, Fei Wang, Shanshan Wang +10
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYImmunologyOncologyDOAJ
  2. Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study
    Masaki Ishida, Tadaaki Yamada, Riko Kamada +19
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyPMCCrossrefEurope PMC
  3. Provider Perspectives on Friedreich Ataxia: A Cross-Sectional Survey to Assess Disease Familiarity and Decision-Making in the US.
    Cuixia Tian, Sheng-Han Kuo, James McKay +8
    Degenerative neurological and neuromuscular diseasePeer-reviewedCC BY-NCFull textNeuroscienceEurope PMCPMC
  4. Omaveloxolone functions as a molecular crowbar-like degrader of STING to alleviate aging-related inflammation.
    Jingyi Zhou, Xinyi Ma, Bing Jiang +16
    Nature communicationsPeer-reviewedCC BYFull textImmunologyEurope PMCPMC
  5. FLOT versus SOX as immunochemotherapy backbones for neoadjuvant or conversion therapy in gastric cancer: efficacy, toxicity, and postoperative safety in a real-world cohort
    Penghui Liu, Na Li, Jiwu Guo +3
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{gallo2026efficacy,
  title = {{Efficacy and Safety of Omaveloxolone in Friedreich Ataxia: Real‐World Data from an Advanced Disease Cohort}},
  author = {Silvia Gallo and Carlo Alberto Artusi and Claudia Ledda and Serena Budicin and Gabriele Imbalzano and Cecilia Buzzelli and Elena Scaglia and Francesca Donetto and Elisa Montanaro and Alberto Romagnolo and Maurizio Zibetti and Mario Giorgio Rizzone and Marco Bozzali and Leonardo Lopiano},
  journal = {Movement Disorders Clinical Practice},
  year = {2026},
  month = oct,
  doi = {10.1002/mdc3.70888},
  url = {https://doi.org/10.1002/mdc3.70888},
}
RIS
TY  - JOUR
TI  - Efficacy and Safety of Omaveloxolone in Friedreich Ataxia: Real‐World Data from an Advanced Disease Cohort
AU  - Silvia Gallo
AU  - Carlo Alberto Artusi
AU  - Claudia Ledda
AU  - Serena Budicin
AU  - Gabriele Imbalzano
AU  - Cecilia Buzzelli
AU  - Elena Scaglia
AU  - Francesca Donetto
AU  - Elisa Montanaro
AU  - Alberto Romagnolo
AU  - Maurizio Zibetti
AU  - Mario Giorgio Rizzone
AU  - Marco Bozzali
AU  - Leonardo Lopiano
PY  - 2026
DA  - 2026/10/29
JO  - Movement Disorders Clinical Practice
DO  - 10.1002/mdc3.70888
UR  - https://doi.org/10.1002/mdc3.70888
SN  - 2330-1619
ER  -